Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Advances in rare cell isolation: an optimization and evaluation study.

Schreier S, Sawaisorn P, Udomsangpetch R, Triampo W.

J Transl Med. 2017 Jan 5;15(1):6. doi: 10.1186/s12967-016-1108-1.

2.

Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, Todoerti K, Lazzari E, Crews LA, Jamieson CH, Ravaioli S, Baccianti F, Garavelli S, Platonova N, Neri A, Chiaramonte R.

Oncotarget. 2016 Aug 30;7(35):56013-56029. doi: 10.18632/oncotarget.10820.

3.

Effect of nutrient starvation on proliferation and cytokine secretion of peripheral blood lymphocytes.

Ota Y, Ishihara S, Otani K, Yasuda K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Kazama S, Yamaguchi H, Sunami E, Kitayama J, Watanabe T.

Mol Clin Oncol. 2016 Apr;4(4):607-610.

4.

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.

Lonial S, Durie B, Palumbo A, San-Miguel J.

Leukemia. 2016 Mar;30(3):526-35. doi: 10.1038/leu.2015.223. Review.

5.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ.

Blood. 2014 Jun 26;123(26):4136-42. doi: 10.1182/blood-2013-12-546374. Erratum in: Blood. 2014 Aug 14;124(7):1201.

6.

The immune system in the pathogenesis of ovarian cancer.

Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS.

Crit Rev Immunol. 2013;33(2):137-64. Review.

7.

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2012 Jan 12;119(2):503-12. doi: 10.1182/blood-2011-07-367052.

8.

Myelomagenesis: capturing early microenvironment changes.

Korde N, Maric I.

Semin Hematol. 2011 Jan;48(1):13-21. doi: 10.1053/j.seminhematol.2010.11.004. Review.

9.

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Mahtouk K, Moreaux J, Hose D, Rème T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B.

BMC Cancer. 2010 May 13;10:198. doi: 10.1186/1471-2407-10-198.

10.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group..

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

11.

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.

Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J.

Haematologica. 2006 Feb;91(2):192-9.

12.

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B.

Blood. 2005 Aug 1;106(3):1021-30.

13.
14.

Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Frassanito MA, Silvestris F, Silvestris N, Cafforio P, Camarda G, Iodice G, Dammacco F.

Clin Exp Immunol. 1998 Nov;114(2):179-88.

15.

Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Lucey DR, Clerici M, Shearer GM.

Clin Microbiol Rev. 1996 Oct;9(4):532-62. Review.

16.

Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.

Hata H, Matsuzaki H, Matsuno F, Sonoki T, Takemoto S, Kuribayashi N, Nagasaki A, Takatsuki K.

Clin Exp Immunol. 1994 May;96(2):370-5.

18.

T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Hilbert DM, Shen MY, Rapp UR, Rudikoff S.

Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):649-53.

Supplemental Content

Support Center